ATE236987T1 - Konsensus-kozak-sequenzen zur säugetier- exprimierung - Google Patents
Konsensus-kozak-sequenzen zur säugetier- exprimierungInfo
- Publication number
- ATE236987T1 ATE236987T1 AT94901599T AT94901599T ATE236987T1 AT E236987 T1 ATE236987 T1 AT E236987T1 AT 94901599 T AT94901599 T AT 94901599T AT 94901599 T AT94901599 T AT 94901599T AT E236987 T1 ATE236987 T1 AT E236987T1
- Authority
- AT
- Austria
- Prior art keywords
- atg
- consensus kozak
- disclosed
- nucleotide
- pyxx
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title 1
- 239000002773 nucleotide Substances 0.000 abstract 3
- 125000003729 nucleotide group Chemical group 0.000 abstract 3
- 108020004705 Codon Proteins 0.000 abstract 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 abstract 2
- 230000001771 impaired effect Effects 0.000 abstract 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 abstract 2
- 229930024421 Adenine Natural products 0.000 abstract 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 229960000643 adenine Drugs 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229940104302 cytosine Drugs 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000002719 pyrimidine nucleotide Substances 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 229940113082 thymine Drugs 0.000 abstract 1
- 230000002103 transcriptional effect Effects 0.000 abstract 1
- 238000011144 upstream manufacturing Methods 0.000 abstract 1
- 229940035893 uracil Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Image Analysis (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97769192A | 1992-11-13 | 1992-11-13 | |
| US08/147,696 US5648267A (en) | 1992-11-13 | 1993-11-03 | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| PCT/US1993/011221 WO1994011523A2 (en) | 1992-11-13 | 1993-11-12 | Fully impaired consensus kozac sequences for mammalian expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE236987T1 true ATE236987T1 (de) | 2003-04-15 |
Family
ID=26845148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94901599T ATE236987T1 (de) | 1992-11-13 | 1993-11-12 | Konsensus-kozak-sequenzen zur säugetier- exprimierung |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US5733779A (de) |
| EP (1) | EP0669986B1 (de) |
| AT (1) | ATE236987T1 (de) |
| CA (1) | CA2149326C (de) |
| DE (2) | DE69332859T2 (de) |
| DK (1) | DK0669986T3 (de) |
| ES (1) | ES2088838T3 (de) |
| PT (1) | PT669986E (de) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6086527A (en) | 1998-04-02 | 2000-07-11 | Scimed Life Systems, Inc. | System for treating congestive heart failure |
| EP1176981B1 (de) * | 1999-05-07 | 2005-11-30 | Genentech, Inc. | Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden |
| US20020058029A1 (en) * | 2000-09-18 | 2002-05-16 | Nabil Hanna | Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination |
| US20050144655A1 (en) * | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6972324B2 (en) * | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
| DE60233738D1 (de) * | 2001-07-10 | 2009-10-29 | Biogen Idec Inc | Hemmung des apoptoseprozesses und verbesserung der zelleistung |
| IL161988A0 (en) | 2001-11-16 | 2005-11-20 | Corporation Idec Pharmaceutica | Polycistronic expression of antibodies |
| CA2477295A1 (en) * | 2002-02-25 | 2003-09-04 | Intronn, Inc. | Trans-splicing mediated imaging of gene expression |
| US20040172667A1 (en) * | 2002-06-26 | 2004-09-02 | Cooper Richard K. | Administration of transposon-based vectors to reproductive organs |
| US20040235011A1 (en) * | 2002-06-26 | 2004-11-25 | Cooper Richard K. | Production of multimeric proteins |
| US7527966B2 (en) | 2002-06-26 | 2009-05-05 | Transgenrx, Inc. | Gene regulation in transgenic animals using a transposon-based vector |
| ES2442615T5 (es) | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| DK1572994T3 (da) | 2002-12-20 | 2007-05-29 | Chromagenics Bv | Midler og fremgangsmåder til fremstilling af en protein gennem chromatinåbnere, som kan göre chromatin mere tilgængeligt for transkriptionsfaktorer |
| EP1596806A4 (de) * | 2003-01-27 | 2007-08-29 | Biogen Idec Inc | Zusammensetzungen und verfahren zur behandlung von krebs mit igsf9 und liv-1 |
| GEP20094629B (en) | 2003-03-19 | 2009-03-10 | Biogen Idec Inc | Nogo receptor binding protein |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| KR101351122B1 (ko) * | 2003-05-09 | 2014-01-14 | 듀크 유니버시티 | Ｃｄ２０-특이적 항체 및 이를 이용한 방법 |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| EP1639009B1 (de) | 2003-05-30 | 2013-02-27 | Merus B.V. | Fab-bibliothek zur herstellung von einer mischung von antikörpern |
| JP4751326B2 (ja) | 2003-09-04 | 2011-08-17 | メダレックス インコーポレイテッド | 発現ベクター |
| WO2005062881A2 (en) | 2003-12-24 | 2005-07-14 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| NZ548828A (en) | 2004-01-20 | 2009-07-31 | Merus B V | Mixtures of binding proteins |
| PT1776136E (pt) | 2004-06-24 | 2012-12-05 | Biogen Idec Inc | Tratamento de estados que envolvem desmielinização |
| US7846438B2 (en) | 2004-08-03 | 2010-12-07 | Biogen Idec Ma Inc. | Methods of promoting neurite outgrowth with soluble TAJ polypeptides |
| US8039230B2 (en) * | 2004-11-08 | 2011-10-18 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
| US20060195935A1 (en) * | 2004-11-08 | 2006-08-31 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
| US8999667B2 (en) * | 2004-11-08 | 2015-04-07 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
| AU2005300503B2 (en) | 2004-11-08 | 2010-12-16 | Chromagenics B.V. | Selection of host cells expressing protein at high levels |
| ES2384391T3 (es) * | 2004-11-08 | 2012-07-04 | Chromagenics B.V. | Selección de células hospedantes que expresan proteína a altos niveles |
| KR20070100346A (ko) | 2005-01-05 | 2007-10-10 | 바이오겐 아이덱 엠에이 인코포레이티드 | 크립토 결합 분자 |
| BRPI0613387A2 (pt) | 2005-07-08 | 2011-01-11 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone |
| AU2006311828B2 (en) | 2005-11-04 | 2013-07-11 | Biogen Ma Inc. | Methods for promoting neurite outgrowth and survival of dopaminergic neurons |
| EP2543384A3 (de) | 2005-12-02 | 2013-04-10 | Biogen Idec MA Inc. | Behandlung von Zuständen mithilfe von Demyelinisation |
| EP1806365A1 (de) | 2006-01-05 | 2007-07-11 | Boehringer Ingelheim International GmbH | Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten |
| US8669345B2 (en) | 2006-01-27 | 2014-03-11 | Biogen Idec Ma Inc. | Nogo receptor antagonists |
| MX2008012146A (es) * | 2006-03-28 | 2008-10-03 | Biogen Idec Inc | Anticuerpos anti-receptor 1 de factor de crecimiento tipo insulina (igf-1r) y uso de los mismos. |
| DK2099826T3 (da) | 2007-01-05 | 2014-01-20 | Univ Zuerich | Anti-beta-amyloid-antistof og anvendelser deraf |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| NO2740744T3 (de) | 2007-01-09 | 2018-08-25 | ||
| BRPI0806849A2 (pt) | 2007-02-02 | 2015-06-23 | Biogen Idec Inc | Uso de semaforin 6a para a promoção de mielinização e diferenciação de oligodendrócitos |
| EP2190480A4 (de) * | 2007-08-28 | 2013-01-23 | Biogen Idec Inc | Anti-igr-1r-antikörper und ihre verwendungen |
| AU2008296386A1 (en) * | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of IGF-1R |
| CN102065895A (zh) * | 2008-04-11 | 2011-05-18 | 比奥根艾迪克Ma公司 | 抗-igf-1r抗体和其它化合物的治疗联合 |
| CA2729961C (en) | 2008-07-09 | 2018-05-01 | Biogen Idec Ma Inc. | Li113, li62 variant co2, anti-lingo antibodies |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | 建南德克公司 | 治療進展型多發性硬化症之方法 |
| WO2010036978A2 (en) * | 2008-09-25 | 2010-04-01 | Transgenrx, Inc. | Novel vectors for production of growth hormone |
| WO2010036979A2 (en) * | 2008-09-25 | 2010-04-01 | Transgenrx, Inc. | Novel vectors for production of interferon |
| WO2010036976A2 (en) * | 2008-09-25 | 2010-04-01 | Transgenrx, Inc. | Novel vectors for production of antibodies |
| AU2009328505B2 (en) | 2008-12-19 | 2014-11-27 | Panima Pharmaceuticals Ag | Human anti-alpha-synuclein autoantibodies |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| CN102341411A (zh) | 2008-12-31 | 2012-02-01 | 比奥根艾迪克Ma公司 | 抗-淋巴细胞毒素抗体 |
| EP2418282B1 (de) | 2009-03-31 | 2017-05-10 | Celltrion, Inc. | Verfahren zur auswahl einer rekombinanten zelllinie mit hoher expression |
| EP2417263B1 (de) * | 2009-04-09 | 2015-09-23 | ProteoVec Holding L.L.C. | Herstellung von proteinen unter verwendung von vektoren auf transposonbasis |
| DK2462237T3 (da) | 2009-08-06 | 2016-03-29 | Cmc Icos Biolog Inc | Fremgangsmåder til forbedring af rekombinant proteinekspression |
| MX341687B (es) | 2010-02-10 | 2016-08-30 | Immunogen Inc | "anticuerpos cd20 y su utilización". |
| TW201217527A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Processable single chain molecules and polypeptides made using same |
| LT2627672T (lt) | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Žmogaus antikūnai prieš tau baltymą |
| CA2818781C (en) | 2010-12-17 | 2019-10-08 | Neurimmune Holding Ag | Human anti-sod1 antibodies |
| EA030777B9 (ru) | 2011-06-23 | 2019-02-28 | Байоджен Интернэшнл Нейросайенз Гмбх | Анти-альфа-синуклеинсвязывающие молекулы |
| WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| ES2740749T3 (es) | 2012-04-20 | 2020-02-06 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
| US9796780B2 (en) | 2012-05-14 | 2017-10-24 | Biogen Ma Inc. | LINGO-2 antagonists for treatment of conditions involving motor neurons |
| US10202595B2 (en) | 2012-06-08 | 2019-02-12 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
| US20150238602A1 (en) | 2012-10-09 | 2015-08-27 | Biogen Idec Ma Inc. | Combination therapies and uses for treatment of demyelinating disorders |
| EP3792278A3 (de) | 2012-12-21 | 2021-05-26 | Biogen MA Inc. | Menschliche anti-tau-antikörper |
| EP3517545A1 (de) | 2012-12-31 | 2019-07-31 | Neurimmune Holding AG | Rekombinante menschliche antikörper zur therapie und vorbeugung von erkrankungen im zusammenhang mit polyomavirus |
| WO2014127215A1 (en) | 2013-02-15 | 2014-08-21 | Biogen Idec Ma Inc. | Optimized factor viii gene |
| SG10201913874TA (en) | 2013-03-15 | 2020-03-30 | Biogen Ma Inc | Factor ix polypeptide formulations |
| EP3160478A4 (de) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Optimiertes faktor-ix-gen |
| AU2015295441B2 (en) | 2014-07-29 | 2020-05-14 | Neurimmune Holding Ag | Human-derived anti-huntingtin (HTT) antibodies and uses thereof |
| BR112017006598A2 (en) | 2014-09-30 | 2018-04-17 | Neurimmune Holding Ag | human derived antidipeptide repeat antibody (dprs) |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| WO2016112270A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
| TWI741992B (zh) | 2015-08-03 | 2021-10-11 | 美商百歐維拉提夫治療公司 | 因子ｉｘ融合蛋白以及其製備及使用方法 |
| LT3411478T (lt) | 2016-02-01 | 2022-09-26 | Bioverativ Therapeutics Inc. | Optimizuoti viii faktoriaus genai |
| AU2017297404A1 (en) | 2016-07-13 | 2019-01-24 | Biogen Ma Inc. | Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders |
| CN110520149A (zh) | 2016-12-02 | 2019-11-29 | 比奥维拉迪维治疗股份有限公司 | 诱导对凝血因子的免疫耐受性的方法 |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| CA3051862A1 (en) | 2017-01-31 | 2018-08-09 | Bioverativ Therapeutics Inc. | Factor ix fusion proteins and methods of making and using same |
| IL322212A (en) | 2017-08-09 | 2025-09-01 | Bioverativ Therapeutics Inc | Nucleic acid molecules and their uses |
| PE20210313A1 (es) | 2018-03-28 | 2021-02-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso |
| WO2019210054A1 (en) | 2018-04-27 | 2019-10-31 | Biogen Ma Inc. | Human-derived anti-(poly-ga) dipeptide repeat (dpr) antibody |
| MA52630B1 (fr) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc. | Procédés de traitement de l'hémophilie a |
| US12037398B2 (en) | 2018-06-04 | 2024-07-16 | Biogen Ma Inc. | Anti-VLA-4 antibodies having reduced effector function |
| CN113227385B (zh) | 2018-08-09 | 2024-12-24 | 比奥维拉迪维治疗股份有限公司 | 核酸分子及其用于非病毒基因疗法的用途 |
| TW202126284A (zh) | 2019-09-30 | 2021-07-16 | 美商百歐維拉提夫治療公司 | 慢病毒載體配製物 |
| CA3183557A1 (en) | 2020-06-24 | 2021-12-30 | Bioverativ Therapeutics Inc. | Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein |
| MX2024002334A (es) | 2021-08-23 | 2024-05-23 | Bioverativ Therapeutics Inc | Genes optimizados del factor viii. |
| AR126845A1 (es) | 2021-08-23 | 2023-11-22 | Bioverativ Therapeutics Inc | Producción de adn de extremo cerrado con secuencias repetidas de terminal invertida |
| CN118019758A (zh) | 2021-09-30 | 2024-05-10 | 比奥维拉迪维治疗股份有限公司 | 编码免疫原性降低的因子viii多肽的核酸 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
-
1993
- 1993-11-12 AT AT94901599T patent/ATE236987T1/de active
- 1993-11-12 PT PT94901599T patent/PT669986E/pt unknown
- 1993-11-12 CA CA002149326A patent/CA2149326C/en not_active Expired - Lifetime
- 1993-11-12 DE DE69332859T patent/DE69332859T2/de not_active Expired - Lifetime
- 1993-11-12 EP EP94901599A patent/EP0669986B1/de not_active Expired - Lifetime
- 1993-11-12 DK DK94901599T patent/DK0669986T3/da active
- 1993-11-12 ES ES94901599T patent/ES2088838T3/es not_active Expired - Lifetime
- 1993-11-12 DE DE0669986T patent/DE669986T1/de active Pending
-
1995
- 1995-06-07 US US08/484,334 patent/US5733779A/en not_active Expired - Lifetime
-
1998
- 1998-01-26 US US09/013,092 patent/US6017733A/en not_active Expired - Lifetime
-
1999
- 1999-03-30 US US09/280,999 patent/US6159730A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69332859T2 (de) | 2003-12-18 |
| EP0669986A1 (de) | 1995-09-06 |
| ES2088838T1 (es) | 1996-10-01 |
| US6159730A (en) | 2000-12-12 |
| CA2149326C (en) | 2007-04-17 |
| DK0669986T3 (da) | 2003-07-28 |
| ES2088838T3 (es) | 2004-01-01 |
| DE669986T1 (de) | 1996-10-10 |
| CA2149326A1 (en) | 1994-05-26 |
| US5733779A (en) | 1998-03-31 |
| DE69332859D1 (de) | 2003-05-15 |
| PT669986E (pt) | 2003-08-29 |
| US6017733A (en) | 2000-01-25 |
| EP0669986B1 (de) | 2003-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE236987T1 (de) | Konsensus-kozak-sequenzen zur säugetier- exprimierung | |
| WO1994011523A3 (en) | Fully impaired consensus kozac sequences for mammalian expression | |
| Nakashima et al. | Molecular cloning of a human cDNA encoding a novel protein, DAD1, whose defect causes apoptotic cell death in hamster BHK21 cells | |
| Miyata et al. | Nucleotide sequence divergence of mouse immunoglobulin gamma 1 and gamma 2b chain genes and the hypothesis of intervening sequence-mediated domain transfer. | |
| BR9508033A (pt) | Cassete de expressão de dna vetor de expressão de levedura célula de levedura processo para produzir um polipeptídeo em levedura | |
| CO4960642A1 (es) | Inhibidores de proteino farnesil transferasas inhibidores de la proteinofarnesiltransferasa y composicio nes que los ocntienen | |
| WO1992001049A3 (en) | Cd53 cell surface antigen and use thereof | |
| ATE66693T1 (de) | Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben. | |
| DK0597960T3 (da) | Behandling af cellepopulationer | |
| ATE275628T1 (de) | Expressionssteigernde sequenzelemente (ease) für eukaryontische expressionssysteme | |
| AU1824992A (en) | Synthetic catalytic oligonucleotide structures containing modified nucleotides | |
| AR056723A2 (es) | Polipeptido purificado metodo para producirlo , metodo para identificarlo y/ o aislarlo composicion farmaceutica que lo comprende, secuencia de acidos nucleicos aislada que codifica dicho polipeptido, vector que contiene a dicha secuencia celula huesped transfectada por dicho vector, sonda nucleotid | |
| Carper et al. | cDNA sequence of a human heat shock protein HSP27 | |
| EP0290419A2 (de) | DNS-Klone von menschlichem Thrombomodulin | |
| DE69936919D1 (en) | Fy7 polymerase | |
| Leder et al. | Characterization, expression, and evolution of the mouse embryonic ζ-globin gene | |
| IL128198A (en) | Isolated nucleic acids and uses thereof for conferring plants with resistance to nematodes and/or aphids | |
| DE59704973D1 (de) | Nucleosid-derivate mit photolabilen schutzgruppen | |
| BR9407693A (pt) | Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto | |
| Ogawa et al. | Molecular cloning, sequence analysis, and expression in Escherichia coli of the cDNA for guanidinoacetate methyltransferase from rat liver. | |
| DE69233612D1 (de) | Verfahren zur bildung einer strukturellen und funktionellen diversität in einer peptidsequenz | |
| ATE296886T1 (de) | Männliche fertilität vermittelnde nukleotidsequenzen und verfahren zu ihrer verwendung | |
| TW343997B (en) | Mutant AOX2 promoter, vector carrying same, transformant, and production of heterologous protein | |
| DE3885395D1 (de) | Expressionsvektor und Verfahren zur Expression von heterologen Proteinen in Säugerzellen. | |
| Wynford‐Thomas et al. | Suppression of transformation and immortality in human/chinese hamster fibroblast hybrids—a model for suppressor gene isolation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0669986 Country of ref document: EP |